Moreover, the reclassified LCC patients presented a significantly lower incidence of TP53 mutation compared with the excluded specimens according to the 2015 WHO criteria (LCC vs non-LCC = 50% vs 93.75%, respectively, p = 0.015). The gene discussed is TP53; the disease is leukoencephalopathy with calcifications and cysts.